Initial Treatment of Venous Thromboembolism

Circulation

Volumn 110, Issue 9 SUPPL., 2004, Pages

  McRae, Simon J ^a,b   Ginsberg, Jeffrey S ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Anticoagulants; Deep venous thrombosis; Heparin; Pulmonary embolism; Thrombosis; Venous thromboembolism

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; ARGATROBAN; DALTEPARIN; ENOXAPARIN; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; STREPTOKINASE; TINZAPARIN; UROKINASE;

BLOOD CLOT LYSIS; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG EMBOLISM; OSTEOPOROSIS; PHYSIOLOGY; PREGNANCY; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PULMONARY EMBOLISM; THROMBOEMBOLISM; THROMBOLYTIC THERAPY; VENOUS THROMBOSIS;

EID: 4544363732     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000140904.52752.0c     Document Type: Review

References (67)

1. White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(Suppl I):I-4-I-8.
2. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep vein thrombosis. Ann Intern Med. 1996;125:1-7.
3. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet. 1960;1:1309-1312.
4. Hyers TM. Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest. 2001;119(Suppl I):176S-193S.
5. Doyle DJ, Turpie AG, Hirsh J, et al. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. Ann Intern Med. 1987;107:441-445.
6. Huisman MV. Buller HR, ten Gate JW, et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep vein thrombosis. Chest. 1989;95:498-502.
7. Hull RD, Hirsh J, Carter CJ, et al. Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Intern Med. 1983;98:891-899.
8. Girard P, Musset D, Parent F, et al. High prevalence of detectable deep venous thrombosis in patients with acute pulmonary embolism. Chest. 1999;116:903-908.
9. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337:688-698.
10. McLean J. The thromboplastic action of cephalin. Am J Physiol. 1916;41:250-257.
11. Rosenberg ED, Lam L. Correlation between structure and function of heparin. Proc Natl Acad Sci USA. 1979;76:1218-1222.
12. Hirsh J. Heparin. N Engl J Med. 1991;324:1565-1574.
13. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119(Suppl I):64S-94S.
14. Choay J, Lormeau JC, Petitou, et al. Structural studies on a biologically active hexasaccharide obtained from heparin. Ann NY Acad Sci. 1981;370:644-649.
15. Hull RD, Raskob GE. Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1986;315:1109-1114.
16. Lagerstedt CI, Olsson CG, Fagher BO, et al. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet. 1985;2:515-518.
17. Hommes DW, Bura A, Mazzolai L. et al. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. Ann Intern Med. 1992;116:279-284.
18. Hirsh J, van Aken WG. Callus AS, et al. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation. 1976;53:691-695.
19. Levine MN. Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med. 1994;154:49-56.
20. Raschke RA, Reilly BM. Guidry JR, et al. The weight-based heparin dosing nomogram compared with a "standard care" nomogram: a randomized controlled trial. Ann Intern Med. 1993;119:874-881.
21. Brill-Edwards P, Ginsberg JS, Johnston M, et al. Establishing a therapeutic range for heparin therapy. Ann Intern Med. 1993;119:104-109.
22. Kitchen S. Problems in laboratory monitoring of heparin dosage. Br J Haematol. 2000;111:397-406.
23. Bates SM, Weitz JI, Johnston M, et al. Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin. Arch Intern Med. 2001;161:385-391.
24. Anand S, Ginsberg JS, Kearon C, et al. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Arch Intern Med. 1996;156:1677-1681.
25. Hull RD, Raskob GE, Brant RF, et al. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med. 1997;157:2562-2568.
26. Anand SS, Bates S, Ginsberg JS, et al. Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin time. Arch Intern Med. 1999;159:2029-2032.
27. Cruickshank MK, Levine MN, Hirsh J, et al. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med. 1991;151:333-337.
28. Hirsh J, Levine MN. Low-molecular-weight heparin. Blood. 1992;79:1-17.
29. Gould MK, Dembitzer AD, Doyle RL, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized controlled trials. Ann Intern Med. 1999;130:800-809.
30. Dolovich LR. Ginsberg JS. Douketis JD, et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type and dosing frequency. Arch Intern Med. 2000;160:181-188.
31. Breddin HK, Hach-Wunderle V, Nakov R, et al. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med. 2001;344:626-631.
32. Hull RD, Raskob GE, Brant RF et al. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. Arch Intern Med. 2000;160:229-236.
33. Merli G, Spiro TE, Olsson CG, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med. 2001;134:191-202.
34. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med. 1997;337:663-669.
35. Wells PS, Kovacs MJ, Bormanis J, et al. Expanding eligibility for out-patient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin. Arch Intern Med. 1998;158:1809-1812.
36. Harrison L. McGinnis J, Crowther M, et al. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med. 1998;158:2001-2003.
37. White RH, Ginsberg JS. Low-molecular-weight heparins: are they all the same? Br J Haematol. 2003;121:12-20.
38. van der Heijden JF, Prins MH, Buller HR. For the initial treatment of venous thromboembolism: are all low-molecular-weight heparin compounds the same? Thromb Res. 2000;100:121-130.
39. Couturaud F, Julian JA, Kearon C. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis. Thromb Haemost. 2001;86:980-984.
40. Greaves M for the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Limitations of the laboratory monitoring of heparin therapy. Thromb Haemost. 2002;87:163-164.
41. Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med. 2002;162:2605-2609.
42. Wilson SJ, Wilbur K, Burton E, et al. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism. Haemostasis. 2001;31:42-48.
43. Hainer JW, Barrett JS, Assaid CA, et al. Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost. 2002;87:817-823.
44. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol. 2003;121:535-555.
45. Chong BH. Heparin-induced thrombocytopenia. J Thromb Haemost. 2003;1:1471-1478.
46. Lindhoff-Last E, Nakov R, Misselwitz F. et al. Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin. Br J Haematol. 2002;118:1137-1142.
47. Warkentin TE. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Recommendations. Arch Pathol Lab Med. 2002;126:1415-1423.
48. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146-153.
49. Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest. 2001;119:1225-1315.
50. Pettila V, Leinonen P, Markkola A, et al. Postpartum bone mineral density in women treated with thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost. 2002;87:182-186.
51. Hull RD, Raskob GE, Rosenbloom D. et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med. 1990;322:1260-1264.
52. Callus A, Jackaman J, Tillett J, et al. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet. 1986;2:1293-1296.
53. Crowther MA. Ginsberg JS, Kearon C. et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med. 1999;159:46-48.
54. Kovacs MJ, Rodger M, Anderson DR, et al. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Ann Intern Med. 2003;138:714-719.
55. Forster AJ, Wells PS. The rationale and evidence for the treatment of lower-extremity deep venous thrombosis with thrombolytic agents. Curr Opin Hematol. 2002;9:437-442.
56. Dalen JE. The uncertain role of thrombolytic therapy in the treatment of pulmonary embolism. Arch Intern Med. 2002;162:2521-2523.
57. Konstantinides S, Giebel A. Heusel G, et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 2002;347:1143-1150.
58. Dalen JE, Alpert JS, Hirsh J. Thrombolytic therapy for pulmonary embolism: is it effective? Is it safe? When is it indicated? Arch Intern Med. 1997;157:2550-2556.
59. Jerjes-Sanchez C, Ramirez-Rivera A, de Lourdes Garcia M, et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. J Thromb Thrombolysis. 1995;2:227-229.
60. Ginsberg JS, Bates SM. Management of venous thromboembolism during pregnancy. J Thromb Haemost. 2003;1:1435-1442.
61. Koopman MM, Buller HR. Short- and long-acting pentasaccharides. J Intern Med. 2003;254:335-342.
62. Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003;349:1695-1702.
63. Bates SM, Weitz JI. Emerging anticoagulant drugs. Arterioscler Thromb Vase Biol. 2003;23:1491-1500.
64. The Matisse Investigators. The MATISSE-DVT trial, a randomized, double-blind study comparing once-daily fondaparinux (Arixtra) with the low-molecular-weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep-vein thrombosis (DVT). J Thromb Haemost. 2003;1(Suppl I):Abstract OC332.
65. Francis CW. Ginsberg JS. Berkowitz SD, et al. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolus: the THRIVE treatment study. Blood. 2003;102:6a.
66. Arcelus JI, Caprini JA, Monreal M, et al. The management and outcome of acute venous thromboembolism: a prospective registry including 4011 patients. J Vasc Surg. 2003;38:916-922.
67. Partsch H. Bedrest versus ambulation in the initial treatment of patients with proximal deep vein thrombosis. Curr Opin Pulm Med. 2002;8:389-393.